In this study, microcin E492 gene from
Klebsiella pneumoniae was screened by using PCR in 45 clinical specimens of patients. Sequencing confirmed the fidelity of amplicon. Results showed a high prevalence of
Klebsiella pneumoniae strains harboring this gene, which can be an explanation of these bacteria being a common microbial flora in some of Iran’s hospitals. More experiments and research in the sources of the microorganisms were carried out, Extraction and separation of microcin E492 gene were also carried out by using standard already prepared strains. For example, the study was done by De Lorenzo et al., The effect of microcin produced by
Klebsiella pneumoniae on
E. coli in a co-culture condition confirmed the sensitivity of
Escherichia coli to microcin. They used various culture for microorganisms but prepared microcin by M9 melted soft agar medium, and finally filtered supernatants [
18]. In contrast, we used 45 clinical specimens of patients for conventional biochemical and standard microbiology tests in initial identification. Microcin E492 is a low molecular weight antibiotic peptides produced by
Enterobacteriaceae with a wide range of antibacterial activity against Gram-negative bacteria. This property can be useful for antibacterial trials.
Hetz et al. (2002) found that microcin E492 has a cytotoxic effect, low molecular weight, and formation of the channel was produced by strains of
Klebsiella pneumoniae. Induction of apoptosis by microcin E492 due to the calcium ion released from intracellular stores. Moreover they found out a specific interaction between bacteriocin and the components of the target cell surface. Microcin amino acid sequence analysis showed that microcin E492 belongs to a new class of bacteriocin pore-forming. They extracted and purified microcin E492 from supernatant cultures of
E. coli VCS257pJEM15 by M9 medium, and then purified it by HPLC method [
19]. Therefore in our study, we extracted microcin E492 from
Klebsiella pneumonia directly.
De Lorenzo et al. found out that the pure product characteristics revealed that microcin E492 is a hydrophobic peptide with molecular weight about 5kD, resistant to heat and acid. Microcin E492 is produced and is active in Gram-negative strains:
E. coli,
Klebsiella,
Salmonella,
Citrobacter,
Enterobacteror erwinia but it is not produced in
Shigella,
Proteus,
Serratia or
Pseudomonas. Furthermore, the sensitivity of some non-agglutinable type strains of Vibrio was observed at high concentrations of microcin. In his study,
Klebsiella pneumonia RYC492 was used to detect microcin E492 and HPLC method was used to purify it [
20]. Because the majority of studies available, used a limited number of samples, this study cannot be statistically compared with the other research findings.
In this study, because of the high importance of microcin E492 in medicine, we focused on its prevalence in bacteria isolated from hospitals. Past and ongoing researches on antimicrobial peptides have shown that these compounds have a great potential to be used in food and medical industries. Discoveries of new antimicrobial peptides and the understanding of the biological process involved in the synthesis, immunity, and regulation of antimicrobial peptides, should play a role in this field, with emphasis on practical applications in the industry [
3]. In this study, we isolated
Klebsiella pneumoniae strains from the burn wounds, urine and respiratory tract in more than 40% of patients’ clinical specimens. In the next step, we screened the Microcin E492 in these isolates. Our result can support high prevalence of
Klebsiella pneumoniae in hospital infections. In other words,
K. pneumoniae can use microcin E492 as a weapon against other microbial flora. As reported in this study, existence of microcin gene in
Enterobacteriaceae can develop them to a dominant microbial flora in human body. In addition, based on the results obtained in this study and the problem of resistance to beta-lactam agents and third generation cephalosporins, which are the most effective broad-spectrum antibiotics in the treatment of many infectious diseases, this is a serious problem for the development, and we also need to replace the new antibiotics.